1-Carbomethoxy-β-Carboline, Derived from <i>Portulaca oleracea </i>L., Ameliorates LPS-Mediated Inflammatory Response Associated with MAPK Signaling and Nuclear Translocation of NF-κB

oleh: Kang-Hoon Kim, Eun-Jae Park, Hyun-Jae Jang, Seung-Jae Lee, Chan Sun Park, Bong-Sik Yun, Seung Woong Lee, Mun-Chual Rho

Format: Article
Diterbitkan: MDPI AG 2019-11-01

Deskripsi

Portulaca oleracea is as a medicinal plant known for its neuroprotective, hepatoprotective, antidiabetic, antioxidant, anticancer, antimicrobial, antiulcerogenic, and anti-inflammatory activities. However, the specific active compounds responsible for the individual pharmacological effects of P. oleracea extract (95% EtOH) remain unknown. Here, we hypothesized that alkaloids, the most abundant constituents in P. oleracea extract, are responsible for its anti-inflammatory activity. We investigated the phytochemical substituents (compounds 1&#8722;22) using nuclear magnetic resonance (NMR) and electrospray ionization mass spectrometry (ESI-MS) and screened their effects on NO production in lipopolysaccharide (LPS)-induced macrophages. Compound 20, 1-carbomethoxy-&#946;-carboline, as an alkaloid structure, ameliorated nitric oxide (NO) production, inducible nitric oxide synthase (iNOS), and proinflammatory cytokines associated with the mitogen-activated protein kinase (MAPK) pathways, p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). Subsequently, we observed that compound 20 suppressed nuclear translocation of nuclear factor &#954;B (NF-&#954;B) using immunocytochemistry. Moreover, we recently reported that compound 8, trans-N-feruloyl-3&#8217;, 7&#8217;-dimethoxytyramine, was originally purified from P. oleracea extracts. Our results suggest that 1-carbomethoxy-&#946;-carboline, the most effective anti-inflammatory agent among alkaloids in the 95% EtOH extract of P. oleracea, was suppressing the MAPK pathway and nuclear translocation of NF-&#954;B. Therefore, P. oleracea extracts and specifically 1-carbomethoxy-&#946;-carboline may be novel therapeutic candidates for the treatment of inflammatory diseases associated with the activation of MAPKs and NF-&#954;B.